Mounjaro 7.5 Kwikpen

Mounjaro 7.5 mg KwikPen contains Tirzepatide as its active ingredient. It is a prescription medicine supplied as a multi-dose prefilled pen. It helps obese or overweight adults lose weight by increasing insulin sensitivity and reducing hunger. Each dose contains 7.5 mg of Tirzepatide in 0.6 mL, and one pen provides four once-weekly doses. The total usable content is 30 mg in 2.4 mL. This presentation is different from the 7.5 mg/0.5 mL single-dose vial.

Mounjaro 7.5 mg KwikPen is used for: Type 2 diabetes mellitus: To improve blood sugar control along with diet and exercise. Weight management: To support weight loss and weight maintenance in eligible adults with obesity or overweight and at least one weight-related health condition. Use it with a reduced-calorie diet and increased physical activity. Use Mounjaro 7.5 mg KwikPen only for the condition for which it has been prescribed.

Use Mounjaro 7.5 mg KwikPen exactly as your doctor prescribed. Treatment with Tirzepatide is usually started at a lower dose and increased gradually based on how you respond to treatment and tolerate the medicine. Mounjaro 7.5 mg KwikPen is generally used once a week. The strength, dosage form and method of administration depend on the product. Follow the administration instructions provided with Mounjaro 7.5 mg KwikPen and those given by your doctor or pharmacist. Do not change the dose or stop treatment without medical advice.

Common side effects: Nausea Diarrhoea Vomiting Constipation Abdominal pain Indigestion Decreased appetite These effects are more common when the dose is increased and often become less noticeable with continued treatment. Serious side effects: Severe allergic reactions Pancreatitis Severe gastrointestinal problems Gallbladder problems Low blood sugar, particularly when used with insulin or sulfonylureas Worsening diabetic eye disease Kidney-function deterioration due to dehydration Seek medical attention for severe or persistent abdominal pain, particularly if the pain spreads to the back. Tell your doctor if you have severe gastrointestinal disease or symptoms of gastroparesis. Tirzepatide slows stomach emptying and may worsen gastrointestinal symptoms. Persistent vomiting or diarrhoea can cause dehydration and may affect kidney function. If you have diabetic retinopathy, tell your doctor about any changes in vision so that your eye condition can be monitored. Tell your doctor before surgery, general anaesthesia or deep sedation because delayed stomach emptying may increase the risk of stomach contents entering the lungs during some procedures.

Pregnancy Unsafe Mounjaro 7.5 mg KwikPen should not be used during pregnancy. If you become pregnant while using Mounjaro 7.5 mg KwikPen or are planning a pregnancy, speak to your doctor about your treatment. Breast Feeding Consult Your Doctor Tell your doctor if you are breastfeeding before using Mounjaro 7.5 mg KwikPen. Your doctor can advise whether it is suitable for you based on your treatment needs and the available information on breastfeeding. Lungs Consult Your Doctor Tell your doctor if you have breathing problems or a lung condition before using Mounjaro 7.5 mg KwikPen. Liver Consult Your Doctor Tell your doctor if you have liver disease before using Mounjaro 7.5 mg KwikPen. A dose adjustment is generally not required for liver impairment, but your doctor will decide whether treatment is suitable for you. Alcohol Consult Your Doctor Speak to your doctor about alcohol while using Mounjaro 7.5 mg KwikPen. Alcohol can affect blood sugar levels and may increase the risk of low blood sugar when Mounjaro 7.5 mg KwikPen is used with insulin or sulfonylureas. Driving Safe Mounjaro 7.5 mg KwikPen is not expected to directly affect your ability to drive. However, low blood sugar c

2 - 8°C

KwikPen